Protective Effects of HDAC6 Inhibitor on Methamphetamine-Induced Neurotoxicity

Abstract

Methamphetamine (METH) is a highly addictive drug that damages the central nervous system, causing blood-brain barrier (BBB) disruption, neuroinflammation, and dopaminergic neuronal damage. This study investigates the effects of SON-7-108, a new HDAC6 inhibitor, on METH-induced damage. In cell studies, SON-7-108 increased microtubule acetylation, reduced pro-inflammatory cytokine levels, and decreased reactive oxygen species (ROS). In METH-treated mice, SON-7-108 reduced BBB permeability, ROS production, and neuroinflammation, while preserving tyrosine hydroxylase (TH) and dopamine transporter (DAT) levels. These findings suggest that SON-7-108 may be a promising treatment for METH addiction.